cas 1255099-13-8|| where to buy Methyl 3-ethynyl-4-methylbenzoate

Nom du produit:Methyl 3-ethynyl-4-methylbenzoate

IUPAC Name:methyl 3-ethynyl-4-methylbenzoate

Unité d'emballage	Stock disponible	Prix($)
CM318788-1g	in stock	Ʀȁư
CM318788-5g	in stock	țưƀ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1255099-13-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1255099-13-8; Formule moléculaire:C11H10O2; Point de fusion:-; Code SMILES:O=C(OC)C1=CC=C(C)C(C#C)=C1; Densité:

: Numéro de catalogue:CM318788; Poids moléculaire:174.2; Point d'ébullition:; N° Mdl:MFCD17926442; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.